Rapid Medical Announces Ahead of Schedule Completion of Patient Enrollment for the TIGER Clinical Study for TIGERTRIEVER Thrombectomy Device

Rapid Medical

PR83590

 

YOKNEAM, Israel, April 08 /PRNewswire=KYODO JBN/ --

 

Rapid Medical [https://www.rapid-medical.com/], a company focused on the

development of next generation neurovascular interventional devices, has

announced that it has completed enrollment in the TIGER (Treatment with Intent

to Generate Reperfusion) study ahead of the planned scheduled. This is a US

based, multi-center study of the performance of TIGERTRIEVER, the company's

novel thrombectomy device for the acute treatment of ischemic stroke. The

TIGERTRIEVER is a fully-visible, controllable stentriever that is adjusted to

fit the dimensions of a blocked blood vessel causing acute ischemic stroke.

Vascular neurologist, Jeffrey Saver M.D., Stroke Neurology Director at

Ronald-Reagan-UCLA Medical Center in Los Angeles, California, and

neurointerventionalist Rishi Gupta M.D., Director, Neurocritical Care at

WellStar Health System, Georgia, are the principal investigators of the study.

 

“It was our honor and pleasure to co-lead this trial and we would like to thank

the patients, their families, and the clinical sites who participated in the

study. Their dedication enabled rapid patient recruitment and trial completion

ahead of schedule, despite the extra challenges of the current medical moment.”

said Prof. Saver.

 

"The TIGERTRIEVER is a new generation stentriever which provides the physician

with enhanced user control. Its unique design will hopefully show that it

addresses the limitations of current devices to provide optimal patient

outcomes. We are looking forward to publishing the data," stated Dr. Gupta.

 

TIGER is a multi-site, IDE study evaluating the safety and effectiveness of

Rapid’s TIGERTRIEVER for treatment of ischemic brain stroke. The study results

will be used as part of the 510K submission of the device for FDA clearance.

The study was completed ahead of schedule and took place at 16 of the leading

stroke centers throughout the U.S and one center in Israel. The TIGERTRIEVER

device has CE mark clearance and is commercially available in Europe; thousands

of ischemic stroke thrombectomy procedures are performed with the device every

year.

 

About Rapid Medical

Rapid Medical is developing game-changing devices for endovascular treatments.

Rapid Medical is the maker of TIGERTRIEVER and COMANECI, the first-ever

adjustable remodeling mesh. TIGERTRIEVER and COMANECI are CE marked for use in

Europe and COMANECI is also FDA approved. The TIGERTRIEVER is an

investigational device and is not available for sale in the United States.

 

More information is available at http://www.rapid-medical.com

 

Contact:

Eitan Havis,

VP of Sales and Marketing,

Rapid Medical

eitan@rapid-medical.com

+972-72-250-3331

 

 

Source: Rapid Medical

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中